<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ABIRATERONE" rxcui="">
<ATC code="L02BX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the abiraterone</DESCRIPTION>
<SEVERITY>Precautions for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BUPROPION" rxcui="42347">
<ATC code="N06AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the flecainide due to decrease of its hepatic metabolism by the bupropion</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CINACALCET" rxcui="407990">
<ATC code="H05BX01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of flecanaide with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DARIFENACIN" rxcui="136198">
<ATC code="G04BD10" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of flecainide, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DULOXETINE" rxcui="72625">
<ATC code="N06AX21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of flecainide with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIRABEGRON" rxcui="1300786">
<ATC code="G04BD12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the flecainide by decrease of its metabolism by the mirabegron</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>230-FLECAINIDE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="FLECAINIDE" rxcui="4441">
<ATC code="C01BC04" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TERBINAFINE" rxcui="37801">
<ATC code="D01AE15" />
<ATC code="D01BA02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the terbinafine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT></COMMENT>
</INTERACTION>
</INTERACTIONS>
